Difficulty: Medium
Average Score: 64%
Practice
The National Institutes of Health (NIH) guidelines for the treatment of asthma recommended institution of routine inhaled corticosteroids when patients are classified as having greater than or equal to which type of asthma?
Correct answer
B
Rationale
In the management of asthma, the National Institutes of Health (NIH) guidelines recommend initiating routine inhaled corticosteroids when patients are classified as having mild persistent asthma or greater. This is because patients with mild persistent asthma experience symptoms more than twice a week but less than once a day, and may have nighttime symptoms more than twice a month.
Option A) Mild intermittent asthma is characterized by symptoms occurring less than twice a week and nighttime symptoms less than twice a month. Patients with this classification do not meet the criteria for routine inhaled corticosteroid use as per NIH guidelines.
Option C) Moderate persistent asthma involves daily symptoms, use of rescue inhaler daily, and nighttime symptoms more than once a week. In this case, NIH guidelines recommend stepping up treatment to include daily inhaled corticosteroids and a long-acting beta-agonist.
Option D) Severe persistent asthma is characterized by continuous symptoms throughout the day, frequent nighttime symptoms, and limitation of physical activity. Management of severe persistent asthma involves high-dose inhaled corticosteroids, long-acting bronchodilators, and possibly oral corticosteroids.
Educationally, understanding the classification of asthma severity and corresponding treatment recommendations is crucial for healthcare professionals involved in the care of asthma patients. Adherence to evidence-based guidelines such as those provided by the NIH can help optimize patient outcomes and minimize the risk of exacerbations. By recognizing the appropriate treatment based on asthma severity, healthcare providers can tailor management strategies to individual patient needs, ultimately improving asthma control and quality of life.
Option A) Mild intermittent asthma is characterized by symptoms occurring less than twice a week and nighttime symptoms less than twice a month. Patients with this classification do not meet the criteria for routine inhaled corticosteroid use as per NIH guidelines.
Option C) Moderate persistent asthma involves daily symptoms, use of rescue inhaler daily, and nighttime symptoms more than once a week. In this case, NIH guidelines recommend stepping up treatment to include daily inhaled corticosteroids and a long-acting beta-agonist.
Option D) Severe persistent asthma is characterized by continuous symptoms throughout the day, frequent nighttime symptoms, and limitation of physical activity. Management of severe persistent asthma involves high-dose inhaled corticosteroids, long-acting bronchodilators, and possibly oral corticosteroids.
Educationally, understanding the classification of asthma severity and corresponding treatment recommendations is crucial for healthcare professionals involved in the care of asthma patients. Adherence to evidence-based guidelines such as those provided by the NIH can help optimize patient outcomes and minimize the risk of exacerbations. By recognizing the appropriate treatment based on asthma severity, healthcare providers can tailor management strategies to individual patient needs, ultimately improving asthma control and quality of life.